New combo therapy shows promise for Tough-to-Treat cancers
Disease control
Completed
This study tested a new combination of two immunotherapy drugs (IO102-IO103 and pembrolizumab) as a first treatment for people with advanced lung, head/neck, or bladder cancer that had spread. The goal was to see if the combo could shrink tumors and delay cancer growth. 63 patien…
Phase: PHASE2 • Sponsor: IO Biotech • Aim: Disease control
Last updated Apr 29, 2026 04:13 UTC